| Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response G Chen, AC Huang, W Zhang, G Zhang, M Wu, W Xu, Z Yu, J Yang, ... Nature 560 (7718), 382-386, 2018 | 2486 | 2018 |
| A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24, 2018 | 1194 | 2018 |
| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, ... Nature medicine 24 (10), 1545-1549, 2018 | 666 | 2018 |
| Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy Y Zhang, R Kurupati, L Liu, XY Zhou, G Zhang, A Hudaihed, F Filisio, ... Cancer cell 32 (3), 377-391. e9, 2017 | 546 | 2017 |
| Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer discovery 8 (2), 196-215, 2018 | 526 | 2018 |
| Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma XH Ma, SF Piao, S Dey, Q Mcafee, G Karakousis, J Villanueva, LS Hart, ... The Journal of clinical investigation 124 (3), 1406-1417, 2014 | 489 | 2014 |
| B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma J Griss, W Bauer, C Wagner, M Simon, M Chen, ... Nature communications 10 (1), 4186, 2019 | 338 | 2019 |
| Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence KM Aird, G Zhang, H Li, Z Tu, BG Bitler, A Garipov, H Wu, Z Wei, ... Cell reports 3 (4), 1252-1265, 2013 | 307 | 2013 |
| Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses I Cañadas, R Thummalapalli, JW Kim, S Kitajima, RW Jenkins, ... Nature medicine 24 (8), 1143-1150, 2018 | 284 | 2018 |
| Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors G Zhang, DT Frederick, L Wu, Z Wei, C Krepler, S Srinivasan, YC Chae, ... The Journal of clinical investigation 126 (5), 1834-1856, 2016 | 277 | 2016 |
| PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer VW Rebecca, MC Nicastri, C Fennelly, CI Chude, JS Barber-Rotenberg, ... Cancer discovery 9 (2), 220-229, 2019 | 222 | 2019 |
| A unified approach to targeting the lysosome's degradative and growth signaling roles VW Rebecca, MC Nicastri, N McLaughlin, C Fennelly, Q McAfee, ... Cancer discovery 7 (11), 1266-1283, 2017 | 180 | 2017 |
| PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas H Lu, S Liu, G Zhang, B Wu, Y Zhu, DT Frederick, Y Hu, W Zhong, ... Nature 550 (7674), 133-136, 2017 | 174 | 2017 |
| Identification of secreted proteins that reflect autophagy dynamics within tumor cells AA Kraya, S Piao, X Xu, G Zhang, M Herlyn, P Gimotty, B Levine, ... Autophagy 11 (1), 60-74, 2015 | 163 | 2015 |
| BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth T Wang, M Xiao, Y Ge, C Krepler, E Belser, A Lopez-Coral, X Xu, G Zhang, ... Clinical cancer research 21 (7), 1652-1664, 2015 | 145 | 2015 |
| A stress-induced early innate response causes multidrug tolerance in melanoma D Ravindran Menon, S Das, C Krepler, A Vultur, B Rinner, S Schauer, ... Oncogene 34 (34), 4448-4459, 2015 | 144 | 2015 |
| Targeting the Warburg effect via LDHA inhibition engages ATF 4 signaling for cancer cell survival G Pathria, DA Scott, Y Feng, J Sang Lee, Y Fujita, G Zhang, AD Sahu, ... The EMBO journal 37 (20), e99735, 2018 | 143 | 2018 |
| A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma C Krepler, K Sproesser, P Brafford, M Beqiri, B Garman, M Xiao, ... Cell reports 21 (7), 1953-1967, 2017 | 142 | 2017 |
| Tumor-associated B-cells induce tumor heterogeneity and therapy resistance R Somasundaram, G Zhang, M Fukunaga-Kalabis, M Perego, C Krepler, ... Nature communications 8 (1), 607, 2017 | 138 | 2017 |
| A modified HSP70 inhibitor shows broad activity as an anticancer agent GM Balaburski, JIJ Leu, N Beeharry, S Hayik, MD Andrake, G Zhang, ... Molecular Cancer Research 11 (3), 219-229, 2013 | 122 | 2013 |
